Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1459
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort ; volume:266 ; number:8 ; day:9 ; month:5 ; year:2019 ; pages:1927-1936 ; date:8.2019
Journal of neurology ; 266, Heft 8 (9.5.2019), 1927-1936, 8.2019
- Urheber
-
Regnault, Antoine
Boroojerdi, Babak
Meunier, Juliette
Bani, Massimo
Morel, Thomas
Cano, Stefan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00415-019-09348-3
- URN
-
urn:nbn:de:101:1-2019122213002576950138
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Regnault, Antoine
- Boroojerdi, Babak
- Meunier, Juliette
- Bani, Massimo
- Morel, Thomas
- Cano, Stefan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prevention of progression in Parkinson’s disease
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Correction: The deficiency of Maged1 attenuates Parkinson’s disease progression in mice
Genetically-informed prediction of short-term Parkinson’s disease progression
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Prevention of progression in Parkinson’s disease
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Correction: The deficiency of Maged1 attenuates Parkinson’s disease progression in mice
Genetically-informed prediction of short-term Parkinson’s disease progression
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Prevention of progression in Parkinson’s disease
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease
Simulating the progression of brain structural alterations in Parkinson’s disease
Correction: The deficiency of Maged1 attenuates Parkinson’s disease progression in mice
Genetically-informed prediction of short-term Parkinson’s disease progression
Evaluating a motor progression connectivity model across Parkinson’s disease stages
Initiation and progression of α-synuclein pathology in Parkinson’s disease
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
The heterogeneity of Parkinson’s disease
The immunology of Parkinson’s disease
Disease progression strikingly differs in research and real-world Parkinson’s populations